The Hearing You Can’t Watch: What the DEA’s Cannabis Rescheduling Fight Means for Everyday Americans (2026)
A federal hearing that could reshape cannabis law is underway. It won’t be livestreamed, the invited participants all oppose the reform, and even the final outcome may not be binding. Here’s a plain-English breakdown of what’s happening and why it matters, minus the political noise.
There is a certain kind of government proceeding that generates enormous headlines and very little clarity, and the DEA’s cannabis rescheduling hearing is shaping up to be a textbook example. If you’ve seen the phrase “Schedule III” floating around your feed and weren’t entirely sure what it meant, whether it was good news, or whether it affected you at all, you are in very good company. The whole thing is procedurally dense, politically charged, and structured in a way that makes it genuinely hard to follow. So let’s cut through it and lay out what’s actually happening, what it could mean, and why an everyday American who uses hemp products should care.
The short version: the federal government is holding a hearing that will help decide whether marijuana gets moved from Schedule I, the most restrictive category in federal drug law, down to Schedule III, a much less restrictive one. The hearing began June 29, 2026, and runs through mid-July, with a break around Independence Day. When it wraps, an administrative law judge will issue a recommendation, and then the DEA and the Justice Department decide what to do with it. That’s the process. The details are where it gets complicated.
What Schedule I Versus Schedule III Actually Means
First, some plain-English background, because the scheduling system is one of those things everyone references and almost nobody explains. The Controlled Substances Act sorts drugs into five schedules. Schedule I is reserved for substances the government classifies as having no accepted medical use and a high potential for abuse. That’s where marijuana has sat since 1970, grouped alongside heroin. Schedule III, by contrast, is for substances with accepted medical uses and a moderate-to-low potential for dependence. It includes things like ketamine, anabolic steroids, and certain codeine formulations.
Moving cannabis from Schedule I to Schedule III would be a significant symbolic and practical shift. It would formally acknowledge, at the federal level, that the plant has legitimate medical uses. It would ease some of the tax and banking burdens that have strangled state-legal cannabis businesses for years. What it would not do is make marijuana federally legal, or turn it into something you can buy at any store nationwide. Schedule III is a reclassification, not a legalization. That distinction gets lost constantly in the coverage, and it matters.
One important thing already happened. As of April 2026, medical cannabis and FDA-approved cannabis products already moved to Schedule III. So the hearing that started June 29 is narrower than it sounds. It’s weighing only whether the rest of the plant, beyond medical and FDA-approved forms, should follow. That’s a meaningful narrowing of scope that most of the headlines have glossed over.
The Part That Has Everyone Talking: Who Got a Seat in the Room
Here’s where the proceeding gets genuinely unusual, and where we’ll stick to the documented facts rather than the political spin. The DEA released its roster of invited participants, the parties it designated as “interested persons” allowed to take part in the hearing, on June 18. There are seven of them. According to the reporting, all seven have positions opposing the rescheduling reform. No designated supporter of the reform made the final list.
The reason, per the DEA’s own stated logic, comes down to a technical definition. To qualify as an “interested person,” the agency decided a party had to be “adversely affected or aggrieved” by the proposed rule. The agency’s reasoning was that since reform groups support moving cannabis off Schedule I, they can’t claim to be harmed by it, and therefore don’t have standing to participate. That single interpretation swept out a long list of would-be participants, including organizations that have represented cannabis consumers for decades and the country’s largest licensed cannabis wholesale distributor.
For context on how much of a departure this is, it’s worth noting that an earlier version of this same proceeding, under the previous administration, seated a much larger group that included both supporters and opponents of the reform. That earlier process had 25 designated participants. This one has seven, all on the same side. The rule didn’t change and the definition didn’t change. The administration running the process did. We’re going to leave the political interpretation of that to the reader, because reasonable people land in different places on it, and our job here is to report what happened, not to tell anyone how to feel about it.
It’s also worth noting where public sentiment sits, since it’s part of the documented record. Researchers at Johns Hopkins and UC San Diego analyzed the roughly 43,000 public comments submitted on the proposed rule and found that about 92 percent supported the Schedule III move or wanted further reform. Whatever one thinks of the hearing’s structure, the public comment record itself leaned heavily in one direction.
A Public Hearing You Can’t Actually Watch
For a proceeding that everyone keeps calling historic, it’s remarkably difficult to observe. The administrative law judge overseeing it ruled that the hearing will not be televised, livestreamed, or broadcast in any form, and barred recording devices from the courtroom. If you want to watch one of the more consequential cannabis policy hearings in a generation, you have to physically travel to a DEA facility in Arlington, Virginia, and hope to claim one of a small number of available seats.
The judge acknowledged in the same order that the national public interest in the issue points toward transparency, even while declining to allow cameras. The earlier version of this hearing under the previous administration was livestreamed. This one is not. Various parties have formally asked the judge to reconsider, arguing that a public hearing isn’t meaningfully public if access depends on physically getting a seat in one room in Virginia. The scope has also been narrowed in other ways, including a ruling that there will be no closing arguments. Take from all of that what you will. We’re reporting it because it’s part of the factual record, not because we’re grinding an axe about it.
Why the Whole Thing Might Not Settle Anything
Here’s the part that should temper anyone expecting a dramatic resolution in either direction. Nothing about this hearing is binding. There’s no verdict at the end. The judge will eventually issue a recommendation, but the DEA and the Justice Department are free to follow it or ignore it, and there’s no deadline forcing them to act at all. Legal experts following the process have noted that both the judge and the DEA operate under no time pressure whatsoever. The judge can take as long as he wants to issue a recommendation, and the DEA can take as long as it wants to respond, if it responds at all.
The recommendation isn’t even limited to a simple yes or no on Schedule III. The judge could recommend Schedule II instead, a tighter classification that would wrap the existing multibillion-dollar cannabis industry in pharmacy-style controls. He could recommend leaving cannabis on Schedule I, exactly where it is. Or he could recommend the move to Schedule III. And whatever he recommends, it’s likely to be challenged in court regardless. Multiple coalitions have already filed petitions seeking to freeze or overturn the rescheduling effort. The courts are probably going to have the last word here, not the hearing itself.
We saw how fragile this kind of process can be last year, when the earlier version of these proceedings stalled out and was ultimately scrapped before reaching a conclusion. Policy experts tracking this one have been openly cautioning that there may be no neat resolution any time soon. So if you’re waiting for a single dramatic moment that clarifies the federal status of cannabis once and for all, this hearing is probably not going to be it. This is the slow, grinding, procedural middle of a story that has been unfolding for decades and will keep unfolding for a while yet.
The Most Important Point for Everyday Consumers: This Is About Marijuana, Not Hemp
Now for the part that actually matters most to the everyday American reading this, and the part that most coverage skips entirely. This entire hearing is about marijuana and its federal scheduling. It is not about hemp. And that distinction is the whole ballgame for the products most people are actually buying and using.
Here’s the difference in plain terms. Marijuana is cannabis above the federal THC threshold, and it’s the plant this DEA hearing is fighting over. Hemp is cannabis at or below that federal threshold, and it was federally legalized nationwide under the 2018 Farm Bill. The CBD products, the federally compliant hemp-derived products, the topicals and tinctures and gummies that millions of Americans have folded into their daily routines, those come from hemp. They already exist in a legal framework that the Schedule I versus Schedule III fight does not directly touch.
This is why the federally legal hemp market has been such a steady, mainstream presence even as the marijuana scheduling debate has dragged on year after year without resolution. The hemp aisle didn’t wait for the DEA to hold a hearing. It got its legal footing in 2018 and has been serving customers ever since. The research supporting the wellness case for these products has kept building the entire time, whether the scheduling fight moves forward or stalls. The recent work on how two out of three Americans report cannabis helps them sleep better and the studies on CBD’s anti-inflammatory effects on skin landed independent of any scheduling decision. The science doesn’t wait for the politics.
None of which means hemp is completely insulated from the broader regulatory picture. It isn’t, and we’ve written about the separate federal hemp rules working their way through the system. But the specific thing happening in that Arlington courtroom, the Schedule I versus Schedule III fight over marijuana, is not the thing that determines whether your CBD topical or your federally compliant hemp gummy is legal. Those are governed by a different framework entirely, one that has been settled and operating since 2018.
The Most Important Point for Everyday Consumers: This Is About Marijuana, Not Hemp
Now for the part that actually matters most to the everyday American reading this, and the part that most coverage skips entirely. This entire hearing is about marijuana and its federal scheduling. It is not about hemp. And that distinction is the whole ballgame for the products most people are actually buying and using.
Here’s the difference in plain terms. Marijuana is cannabis above the federal THC threshold, and it’s the plant this DEA hearing is fighting over. Hemp is cannabis at or below that federal threshold, and it was federally legalized nationwide under the 2018 Farm Bill. The CBD products, the federally compliant hemp-derived products, the topicals and tinctures and gummies that millions of Americans have folded into their daily routines, those come from hemp. They already exist in a legal framework that the Schedule I versus Schedule III fight does not directly touch.
This is why the federally legal hemp market has been such a steady, mainstream presence even as the marijuana scheduling debate has dragged on year after year without resolution. The hemp aisle didn’t wait for the DEA to hold a hearing. It got its legal footing in 2018 and has been serving customers ever since. The research supporting the wellness case for these products has kept building the entire time, whether the scheduling fight moves forward or stalls. The recent work on how two out of three Americans report cannabis helps them sleep better and the studies on CBD’s anti-inflammatory effects on skin landed independent of any scheduling decision. The science doesn’t wait for the politics.
None of which means hemp is completely insulated from the broader regulatory picture. It isn’t, and we’ve written about the separate federal hemp rules working their way through the system. But the specific thing happening in that Arlington courtroom, the Schedule I versus Schedule III fight over marijuana, is not the thing that determines whether your CBD topical or your federally compliant hemp gummy is legal. Those are governed by a different framework entirely, one that has been settled and operating since 2018.
What This Means If You’re Just Trying to Live Your Life
Strip away the procedural drama and here’s the practical takeaway for a regular person who uses or is curious about hemp products. In the near term, very little changes for you regardless of how this hearing goes. The federally legal hemp products you can buy today, you’ll still be able to buy tomorrow. The scheduling fight is about a different category of cannabis and a different set of regulatory questions. If the reform eventually goes through, it mostly affects the state-licensed marijuana industry, its tax burden, and its banking access, not the federally compliant hemp market that most everyday wellness customers actually shop in.
In the longer term, the direction of travel is worth understanding, because it’s part of a broader normalization that has been reshaping how Americans relate to this plant. The fact that the federal government is holding any hearing at all about moving cannabis off Schedule I would have been close to unthinkable a couple of decades ago. Whatever the outcome, the mere existence of the proceeding reflects how far the mainstream conversation has moved. That shift shows up everywhere, from the way American dads talk openly with their kids about responsible cannabis use to the growing body of research treating cannabinoids as a serious wellness category rather than a fringe curiosity.
The honest bottom line is that federal cannabis policy is going to keep being messy, slow, and contested for a while yet. That’s just the reality of a big country working through a complicated issue with a lot of competing interests. In the meantime, the federally legal hemp market keeps doing what it’s been doing since 2018: serving customers, funding real research, and operating in a settled legal framework while the marijuana scheduling fight grinds on separately.
Why Buying From a Transparent Brand Matters More Than Ever During Uncertain Times
Here’s the throughline that connects the political noise to a practical decision you can actually control. When the regulatory environment is uncertain and constantly shifting, the single best thing you can do as a consumer is buy from brands that operate cleanly and transparently no matter what the rules are doing. A brand that publishes its lab results, sources its hemp responsibly, and manufactures under strict quality standards is a brand that’s built to weather regulatory change, because it’s already operating above the bar that any new rule is likely to set.
That’s the entire operating philosophy behind Workman’s Relief. Every product carries a publicly available Certificate of Analysis showing exactly what’s in it and confirming it’s screened for contaminants. The CBD is USDA Certified Organic, grown on Wisconsin soil. Everything is manufactured in-house in our own GMP-certified facility. Our products are federally compliant hemp-derived products, operating in the settled framework the 2018 Farm Bill created, not in the contested marijuana-scheduling space that Arlington courtroom is fighting over.
When the news is full of closed-door hearings and shifting federal positions, the value of a brand that just does the right thing consistently goes up, not down. You shouldn’t have to be a policy expert to know whether the product you’re putting on your body or in your body is clean and honest. The lab report tells you. The organic certification tells you. The in-house manufacturing tells you. That’s the kind of certainty that doesn’t depend on which way a federal hearing breaks.
The Long View: America Is Slowly Working This Out
Step all the way back and there’s a bigger, more optimistic story here than the procedural mess suggests. The United States has spent about a century wrestling with how to regulate a plant that humans have used for many thousands of years. The current hearing, with all its awkwardness, is one more chapter in that long, slow, deeply American process of sorting out a hard question through public institutions, legal challenges, and the steady pressure of public opinion. It’s messy because democracy is messy. It’s slow because getting big things right usually is.
What’s genuinely encouraging is that underneath the political noise, the country keeps moving toward a more honest, evidence-based relationship with cannabinoids. The research keeps getting better. The stigma keeps fading. The federally legal hemp market keeps giving Americans access to clean, tested, transparently made products while the larger legal questions get sorted out through the proper channels. However this specific hearing resolves, and it may not resolve cleanly, the broader direction has been remarkably consistent.
For our part, we’ll keep doing what we’ve always done. Making clean, lab-tested, federally compliant hemp products for working Americans who want a trustworthy option, and letting the policy process play out in Washington while we focus on the thing we can actually control, which is the quality of what we put in the bottle. The 15% discount for veterans and first responders remains standing policy. The Subscribe & Save program is there for the routine that builds over time. The lab reports stay public. The standard doesn’t move, no matter what happens in that courtroom in Virginia.
The politics will sort themselves out eventually. In the meantime, the plant, the research, and the people who want clean products aren’t waiting around. Neither are we.
Browse the full Workman’s Relief lineup →
Subscribe & Save | Veterans & First Responders: 15% Off | View Our Certificates of Analysis | Find a Retail Location
Our Recommendations//
No comment yet, add your voice below!